FDA green-lights Cordis vascular stent for SFA, PPA

Editorial Staff | | Cardiovascular Business | Vascular & Endovascular

The FDA has approved Cordis' S.M.A.R.T. Control vascular stent systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA).

The S.M.A.R.T. stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the U.S. with both iliac and SFA indications. The clinical data supporting the FDA approval of the S.M.A.R.T. stent for use in the peripheral vasculature was obtained through the STROLL investigational device exemption (IDE) trial that enrolled 250 patients at 39 clinical sites within the U.S.

Editorial Staff

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."